Bladder battle: full or empty to ease radiation side effects?
NCT ID NCT06651697
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether having a full or empty bladder during pelvic radiation therapy reduces short-term side effects like bladder or bowel irritation. 300 adults with pelvic cancers (genitourinary, gynecological, or gastrointestinal) will be randomly assigned to one of the two bladder protocols. The main goal is to see which approach leads to fewer moderate-to-severe side effects within 3 months after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Radiation therapy with full or empty bladder protocol
- What this could lead to
- If this trial succeeds, it could show that a simple change in bladder filling during radiation reduces short-term side effects like bladder or bowel irritation.
- What could go wrong
- This is a Phase 3 trial, but the benefit may be small or not apply to all pelvic cancers. Side effects from radiation itself remain a risk regardless of bladder fullness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PELVIC NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of California, San Diego
RECRUITINGSan Diego, California, 92093, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.